A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

Summary

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).

Timeline

Start

2026-03-05

Primary completion

2028-11-30

Completion

2029-03-30

Drugs

Indications